keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28102464/a-phase-i-and-pharmacokinetic-study-of-afilbercept-with-folfiri-comparison-of-chinese-and-caucasian-populations
#1
Jianming Xu, Yingxin Li, Xing Sun, Dongsheng Zhang, Rongrui Liu, Samira Ziti-Ljajic, Dongmei Shi, Fengying Xue, Nathalie Le Bail, Ruihua Xu
Background This study assessed the preliminary safety, pharmacokinetics (PK) and anti-tumor effects of aflibercept in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in Chinese patients with previously-treated advanced solid malignancies. Patients and Methods This open-label single-arm Phase I study conducted at two centers in China included adult (≥18 years) patients with metastatic or unresectable solid malignancies who had received ≥1 prior treatment. Patients received aflibercept 4 mg/kg IV on Day 1 followed by FOLFIRI over Days 1 and 2 every 2 weeks, and were assessed for safety, tumor response, PK parameters and immunogenicity...
January 19, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28101043/effects-of-disseminated-mycobacterial-infection-on-age-related-macular-degeneration
#2
Geoffrey Collett, Natalia Lopez, Pedro F Lopez
Our patient, in the 7th decade of life, presented with worsening blurry vision over 3 weeks. The pertinent history included nonexudative age-related macular degeneration, recent pulmonary mycobacterial infection, and autoimmune pancreatitis. The patient had decreased visual acuity in both eyes; the remaining findings of our examination were relatively benign. The diagnosis of bilateral exudative age-related macular degeneration was aided by ocular imaging. Not only were exudative changes confirmed, but one modality suggested an underlying occult choroiditis, which presumably fueled a local inflammatory drive leading to evolution of the disease...
September 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28100839/tyrosine-kinase-blocking-collagen-iv-derived-peptide-suppresses-ocular-neovascularization-and-vascular-leakage
#3
Raquel Lima E Silva, Yogita Kanan, Adam C Mirando, Jayoung Kim, Ron B Shmueli, Valeria E Lorenc, Seth D Fortmann, Jason Sciamanna, Niranjan B Pandey, Jordan J Green, Aleksander S Popel, Peter A Campochiaro
Vascular endothelial growth factor (VEGF)-neutralizing proteins provide benefit in several retinal and choroidal vascular diseases, but some patients still experience suboptimal outcomes, and the need for frequent intraocular injections is a barrier to good outcomes. A mimetic peptide derived from collagen IV, AXT107, suppressed subretinal neovascularization (NV) in two mouse models predictive of effects in neovascular age-related macular degeneration (NVAMD) and inhibited retinal NV in a model predictive of effects in ischemic retinopathies...
January 18, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28079756/optical-coherence-tomography-angiography-changes-in-early-type-3-neovascularization-after-anti-vascular-endothelial-growth-factor-treatment
#4
Alexandra Miere, Giuseppe Querques, Oudy Semoun, Francesca Amoroso, Olivia Zambrowski, Thibaut Chapron, Vittorio Capuano, Eric H Souied
PURPOSE: To investigate the morphologic changes on optical coherence tomography angiography (OCTA) of treatment-naive Type 3 neovascularization secondary to exudative age-related macular degeneration after 1 year of anti-vascular endothelial growth factor therapy. METHODS: Consecutive patients diagnosed with treatment-naive early-stage Type 3 neovascularization were enrolled in this retrospective study. All patients underwent color fundus photographs/MultiColor (Heidelberg Engineering) imaging, fluorescein angiography, indocyanine green angiography, structural spectral domain OCT, and OCTA Optovue RTVue XR Avanti (Optovue) at baseline, and repeated OCTA and structural spectral domain OCT at Month 12...
January 10, 2017: Retina
https://www.readbyqxmd.com/read/28078129/osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#5
Hani Mawardi, Peter Enzinger, Nadine McCleary, Reshma Manon, Alessandro Villa, Nathaniel Treister, Sook-Bin Woo
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors. We report three patients without a history of the use of medications known to cause MRONJ presenting with jaw osteonecrosis typical for MRONJ following therapy with ziv-aflibercept. All patients had metastatic gastrointestinal cancer treated with ziv-aflibercept and were evaluated for MRONJ because of exposed bone in the oral cavity...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28076566/efficacy-of-aflibercept-on-exudative-age-related-macular-degeneration-in-patients-exhibiting-complete-ranibizumab-resistance-and-tachyphylaxis
#6
Gokcen Gokce, Ali Hakan Durukan, Mehmet Talay Koylu, Murat Kucukevcilioglu
Purpose: The present study compared the efficacy of aflibercept for neovascular age-related macular degeneration (NV-AMD) in patients with complete ranibizumab resistance and tachyphylaxis. Methods: Forty-four eyes of 38 neovascular age-related macular degeneration patients were evaluated. Eyes were divided into a complete resistance group (n=23 eyes) and tachyphylaxis group (n=21 eyes). Results: After three injections, eight (38.1%) patients in the tachyphylaxis group and nine (39...
November 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/28060392/intravitreal-aflibercept-for-neovascular-polypoidal-choroidal-vasculopathy-in-a-predominantly-non-asian-population-rival-results
#7
Amina Farooq, Heather Frazier, William B Marcus, Chelsea Fechter, Harinderjit Singh, Dennis M Marcus
BACKGROUND AND OBJECTIVE: To evaluate safety and efficacy of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) injection (IAI) for the treatment of neovascular polypoidal choroidal vasculopathy (PCV) in a predominantly non-Asian population. PATIENTS AND METHODS: This was an open-label, prospective, unmasked, nonrandomized clinical trial. Twenty eyes with neovascular PCV received monthly 2.0 mg IAI for 3 months followed by mandatory IAI every 2 months for 12 months...
January 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28060148/short-term-safety-of-2-mg-intravitreal-ziv-aflibercept
#8
Jay Chhablani, Chintan Jethalal Dedhia, Hari K Peguda, Michael Stewart
PURPOSE: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). METHODS: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30...
January 2, 2017: Retina
https://www.readbyqxmd.com/read/28038924/coats-disease-with-macular-oedema-responsive-to-aflibercept-and-argon-laser
#9
M C Guixeres Esteve, A O Pardo Saiz
CLINICAL CASE: A 14 year-old boy with Coats' disease in his right eye, presented with a visual acuity (VA) of 0.1, micro-aneurysms, exudates, a macular oedema of 959 microns, and peripheral telangiectasias. After 12 months follow-up with 6 ranibizumab injections and 3 sessions of argon laser photocoagulation, the macular oedema remained and VA was 0.2. Following 4 aflibercept injections and another 2 laser sessions, he had a good foveal slope and a VA of 0.5, with no recurrences in the last 12 months...
December 27, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28033280/stereotactic-radiotherapy-in-neovascular-age-related-macular-degeneration-real-life-efficacy-and-morphological-evaluation-of-the-outer-retina-choroid-complex
#10
Mahdy Ranjbar, Maximilian Kurz, Annekatrin Holzhey, Corinna Melchert, Dirk Rades, Salvatore Grisanti
Stereotactic radiotherapy (SRT) is a new approach to treat neovascular age-related macular degeneration (nAMD). The INTREPID trial suggested that SRT could reduce the frequency of regular intravitreal injections (IVIs) with antivascular endothelial growth factor drugs, which are necessary to control disease activity. However, the efficacy of SRT in nAMD and resulting morphological changes have not been validated under real-life circumstances, an issue, which we would like to address in this retrospective analysis...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28025473/-target-therapy-in-unresectable-or-metastatic-colorectal-cancer
#11
REVIEW
Jae Hyun Kim, Seun Ja Park
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in Korea. Despite recent developments in the treatment of CRC, the median overall survival time in patients with metastatic CRC is less than 30 months. The biologic agents that target the epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have proven clinical benefits in the treatment of patient with metastatic CRC. Anti-EGFR agents, including cetuximab and panitumumab, as well as anti-VEGF agents, including bevacizumab, aflibercept, ramucirumab, and regorafenib have been shown to extend survival in combination with cytotoxic chemotherapy...
December 25, 2016: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/28017484/choroidal-haemangioma-and-photodynamic-therapy-anatomical-and-functional-response-of-patients-with-choroidal-hemangioma-treated-with-photodynamic-therapy
#12
O Subirà, H Brosa, D Lorenzo-Parra, L Arias-Barquet, J Català-Mora, E Cobos, P Garcia-Bru, M J Rubio-Caso, J M Caminal-Mitjana
OBJECTIVE: To study the effectiveness and limitations of photodynamic therapy (PDT) as treatment of choice in patients with symptomatic circumscribed choroidal haemangioma. METHODS: A retrospective study was conducted on 16 patients (13 men and 3 women, with mean age of 54.88 years) with circumscribed choroidal haemangioma, who attended our centre and were treated with PDT in the last 7 years. RESULTS: All patients had circumscribed choroidal haemangioma, which caused a decrease in visual acuity (VA) secondary to the presence of intraretinal microcystic oedema or neurosensory detachment...
December 22, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28006063/intravitreal-aflibercept-injection-in-eyes-with-substantial-vision-loss-after-laser-photocoagulation-for-diabetic-macular-edema-subanalysis-of-the-vista-and-vivid-randomized-clinical-trials
#13
Charles C Wykoff, Dennis M Marcus, Edoardo Midena, Jean-François Korobelnik, Namrata Saroj, Andrea Gibson, Robert Vitti, Alyson J Berliner, Zinaria Williams Liu, Oliver Zeitz, Carola Metzig, Thomas Schmelter, Jeffrey S Heier
Importance: Information on the effect of anti-vascular endothelial growth factor therapy in eyes with diabetic macular edema (DME) with vision loss after macular laser photocoagulation is clinically valuable. Objective: To evaluate visual and anatomic outcomes in a subgroup of macular laser photocoagulation treatment control (hereafter laser control) eyes with substantial vision loss receiving treatment with intravitreal aflibercept injection. Design, Setting, and Participants: This investigation was a post hoc analysis of a subgroup of laser control eyes in 2 phase 3 trials-VISTA (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema) and VIVID (Intravitreal Aflibercept Injection in Vision Impairment Due to DME)-in a multicenter setting...
December 22, 2016: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28006049/further-scrutiny-of-vision-outcomes-when-aflibercept-is-used-as-rescue-treatment-for-eyes-with-diabetic-macular-edema-treated-with-laser
#14
Maureen G Maguire
No abstract text is available yet for this article.
December 22, 2016: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28005721/permeability-and-anti-vascular-endothelial-growth-factor-effects-of-bevacizumab-ranibizumab-and-aflibercept-in-polarized-retinal-pigment-epithelial-layer-in-vitro
#15
Naoya Yoshihara, Hiroto Terasaki, Makoto Shirasawa, Hiroki Kawano, Shozo Sonoda, Munekazu Yamaguchi, Teruto Hashiguchi, Toshio Hisatomi, Tatsuro Ishibashi, Taiji Sakamoto
PURPOSE: To determine the effects of bevacizumab, ranibizumab, and aflibercept on the permeability and the effects of anti-vascular endothelial growth factor (VEGF) on highly polarized retinal pigment epithelial cells (RPECs) in vitro. METHODS: Highly polarized RPECs were cultured in the upper chamber of a Transwell system. Anti-VEGF antibodies were added to the upper chamber, and the concentrations of the drugs in the lower chambers were measured. The permeability rates of the three anti-VEGF drugs through the RPEC layer and the concentration of VEGF in each chamber were determined...
January 2017: Retina
https://www.readbyqxmd.com/read/28005663/type-1-versus-type-3-neovascularization-in-pigment-epithelial-detachments-associated-with-age-related-macular-degeneration-after-anti-vascular-endothelial-growth-factor-therapy-a-prospective-study
#16
Xuejing Chen, Mayss Al-Sheikh, Clement K Chan, Amir H Hariri, Prema Abraham, Maziar Lalezary, Steven G Lin, SriniVas Sadda, David Sarraf
PURPOSE: To evaluate the response to aflibercept therapy for Type 1 and Type 3 neovascularization in pigment epithelial detachments associated with treatment-naive, neovascular age-related macular degeneration. METHODS: In this multicentered, prospective study, eligible eyes underwent an intravitreal aflibercept injection protocol for 12 months. Visual acuity and morphologic features of the pigment epithelial detachments were compared at baseline and follow-up intervals between eyes with Type 1 versus Type 3 neovascularization...
December 2016: Retina
https://www.readbyqxmd.com/read/28003780/aflibercept-in-refractory-wet-amd-treated-with-ranibizumab-anatomical-and-visual-outcome
#17
Sleiman Abou-Ltaif
PURPOSE: To assess the anatomical outcome of patients with exudative age-related macular degeneration resistant to ranibizumab treated with aflibercept. METHOD: Prospective, interventional, case series, where we treated a group of patients deemed resistant to Ranibizumab after 6 months of persistence of intra- or subretinal fluid despite continuous treatment. RESULTS: The study included 17 patients, 3 males and 14 females. The average males age was 85 (range 83-87), and that of females was 79...
October 2016: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28002269/efficacy-of-intravitreal-aflibercept-in-macular-telangiectasia-type-1-is-linked-to-the-ocular-angiogenic-profile
#18
Laura Kowalczuk, Alexandre Matet, Ali Dirani, Alejandra Daruich, Aude Ambresin, Irmela Mantel, Richard F Spaide, Natacha Turck, Francine Behar-Cohen
PURPOSE: To evaluate intravitreal aflibercept in macular telangiectasia Type 1 (MacTel 1) patients and measure their ocular angiogenic profile. METHODS: Eight subjects with MacTel 1 refractory to bevacizumab, ranibizumab, or laser therapy and switched to aflibercept were included. Best-corrected visual acuity, central macular thickness, and cystic areas quantified on optical coherence tomography B-scans were assessed during 12 months. Perifoveal capillary densities were measured on optical coherence tomography angiography...
December 20, 2016: Retina
https://www.readbyqxmd.com/read/28002268/choroidal-thickness-as-a-prognostic-factor-of-photodynamic-therapy-with-aflibercept-or-ranibizumab-for-polypoidal-choroidal-vasculopathy
#19
Yoichi Sakurada, Atsushi Sugiyama, Naohiko Tanabe, Wataru Kikushima, Atsuki Kume, Hiroyuki Iijima
PURPOSE: To investigate factors associated with visual improvement and retreatment 12 months after a combination therapy of intravitreal injection of ranibizumab or aflibercept followed by photodynamic therapy for polypoidal choroidal vasculopathy. METHODS: Changes in the best-corrected visual acuity and the subfoveal thickness of the retina and choroid were studied in 56 consecutive eyes with polypoidal choroidal vasculopathy treated initially with a combination therapy of either intravitreal ranibizumab injection (n = 23) or intravitreal aflibercept injection (n = 33) followed by photodynamic therapy...
December 20, 2016: Retina
https://www.readbyqxmd.com/read/28000147/erratum-to-aflibercept-a-new-way-to-target-angiogenesis-in-the-second-line-treatment-of-metastatic-colorectal-cancer-mcrc
#20
Mario Scartozzi, Loic Vincent, Marielle Chiron, Stefano Cascinu
No abstract text is available yet for this article.
December 20, 2016: Targeted Oncology
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"